NCT00568945View on ClinicalTrials.gov

Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2008

Conditions
Atrial Fibrillation
Interventions
DRUG

Capadenoson (BAY68-4986)

4 mg BAY68-4986 for five days

Trial Locations (1)

99084

Erfurt

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00568945 - Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation. | Biotech Hunter | Biotech Hunter